Market Exclusive

MERCK & CO., INC. (NYSE:MRK) Files An 8-K Submission of Matters to a Vote of Security Holders

MERCK & CO., INC. (NYSE:MRK) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.

Submission of Matters to a Vote of Security Holders.
(a)
The Annual Meeting of Shareholders of Merck Co., Inc. (the
“Company”) was held on May 23, 2017.
(b)
Shareholders voted on the matters set forth below:
Item 1.
All of the following persons nominated were elected to
serve as directors and received the number of votes set
forth opposite their respective names:
Names
Votes
For
Votes
Against
Abstentions
Broker
Non-Votes
Leslie A. Brun
1,913,570,500
80,741,934
4,807,908
382,947,240
Thomas R. Cech, Ph.D.
1,986,322,452
8,845,888
3,952,002
382,947,240
Pamela J. Craig
1,988,464,681
6,530,122
4,125,539
382,947,240
Kenneth C. Frazier
1,906,531,905
80,110,591
12,477,846
382,947,240
Thomas H. Glocer
1,978,350,550
16,678,177
4,091,615
382,947,240
Rochelle B. Lazarus
1,978,253,209
16,188,730
4,678,403
382,947,240
John H. Noseworthy, M.D.
1,987,289,303
7,871,409
3,959,630
382,947,240
Carlos E. Represas
1,977,906,630
17,156,920
4,056,792
382,947,240
Paul B. Rothman, M.D.
1,988,103,870
7,111,688
3,904,784
382,947,240
Patricia F. Russo
1,690,919,415
303,263,696
4,937,231
382,947,240
Craig B. Thompson, M.D.
1,986,996,094
8,162,837
3,961,411
382,947,240
Wendell P. Weeks
1,725,948,887
269,137,168
4,034,287
382,947,240
Peter C. Wendell
1,974,632,978
20,421,145
4,066,219
382,947,240
Item 2.
A proposal to approve, by non-binding advisory vote, the
compensation of our Named Executive Officers received the
following votes:
For
Against
Abstained
Broker
Non-Votes
1,897,185,596
91,226,313
10,708,433
382,947,240
Item 3.
A proposal to approve, by non-binding advisory vote, the
frequency of future votes to approve the compensation of
our Named Executive Officers received the following votes:
1 Year
2 Years
3 Years
Abstained
Broker
Non-Votes
1,793,458,522
7,664,645
191,679,352
6,317,823
382,947,240
Item 4.
A proposal to ratify the appointment of
PricewaterhouseCoopers LLP as the Company’s independent
registered public accounting firm for 2017 received the
following votes:
For
Against
Abstained
2,340,354,229
35,103,594
6,609,759
Item 5. A shareholder proposal requesting an independent Board
chairman received the following votes:
For
Against
Abstained
Broker
Non-Votes
928,762,128
1,061,968,067
8,390,147
382,947,240
Item 6.
A shareholder proposal concerning employee practices in
Israel/Palestine received the following votes:
For
Against
Abstained
Broker
Non-Votes
48,105,678
1,832,554,849
118,459,815
382,947,240
Item 7.
A shareholder proposal requesting a report on conducting
business in conflict-affected areas received the following
votes:
For
Against
Abstained
Broker
Non-Votes
451,496,451
1,463,065,062
84,558,829
382,947,240
Item 8.
A shareholder proposal requesting a report on Board
oversight of product safety and quality received the
following votes:
For
Against
Abstained
Broker
Non-Votes
130,790,903
1,795,383,307
72,946,132
382,947,240
A majority of votes cast was required for the proposals, other than
the vote relating to frequency of compensation votes, to be
approved.
(d)
Based on the voting results set forth in (b) (3) above, the
Company’s Board of Directors has determined that the Company
will hold an annual non-binding advisory vote on the
compensation of the Named Executive Officers listed in the
proxy statement for its Annual Meeting of Shareholders.

About MERCK & CO., INC. (NYSE:MRK)
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company’s animal health products are sold to veterinarians, distributors and animal producers. MERCK & CO., INC. (NYSE:MRK) Recent Trading Information
MERCK & CO., INC. (NYSE:MRK) closed its last trading session down -0.18 at 64.75 with 7,072,657 shares trading hands.

Exit mobile version